Fennec Pharmaceuticals (NASDAQ:FENC) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) in a report released on Friday morning, Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q1 2024 earnings at $0.03 EPS, Q2 2024 earnings at $0.10 EPS, Q3 […]

Related Keywords

United States ,Gendell Jeffrey ,Harbert Fund Advisors Inc ,Institutional Trading Of Fennec Pharmaceuticals ,Fennec Pharmaceuticals Price Performance ,Fennec Pharmaceuticals ,Fennec Pharmaceuticals Inc ,Analyst Recommendations For Fennec Pharmaceuticals ,Opaleye Management Inc ,News Ratings For Fennec Pharmaceuticals Daily ,Get Rating ,Fund Advisors ,Pharmaceuticals Inc ,Sodium Thiosulfate ,Fennec Pharmaceuticals Daily ,Nasdaq Fenc ,Pufenc ,Medical ,Reiterated Rating ,Hc Wainwright ,